AMW GmbH

🎉 Happy birthday, AMW GmbH! 🎉   We are proudly celebrating our 16th anniversary this month! Since July 2008, AMW has been on an incredible journey of innovation, growth and success. 🚀   A big thank you to our fantastic team who work tirelessly to make our vision a reality. Your dedication and passion are at the heart of our success. 💪   Many thanks also to our valued customers and partners for their continued trust and support. Together we have achieved great milestones and we look forward to many more years of collaboration. Let's toast to the past 16 years and look forward to the future! 🥂   #AMW #Companyanniversary #16years #Innovation #Teamwork

AMW GmbH at CPHI South East Asia! We are excited to be on site in Bangkok to unlock the potential of ASEAN’s pharmaceutical markets and engage with current and future business partners. Let us know if you are visiting as well, Joerg Serafimov, PhD and Kristian Laufer are looking forward to discussing with you! Please reach out to them directly.    See the event site for further information: https://lnkd.in/gMRMR2u   #CPHI #AttheheartofPharma

AMW GmbH further strengthens its management team: We are happy to announce that Kerstin Ledermann joined AMW on July 1, 2024, as Vice President People & General Affairs. She is an experienced manager and generalist with a track record of more than 20 years as head of Human Resources and management team member in internationally operating medium-sized companies.   We are delighted to have Kerstin on board and extend a warm welcome on behalf of the whole team. With her extensive expertise and dedication, we are continuing to foster a working environment in which employees can count on openness, respect, freedom and mutual support, which is an essential prerequisite for achieving our ultimate goal of providing patients worldwide with improved therapies and superior drug delivery systems.   Again, welcome to the team!   #HumanResources #People #DrugDeliverySystems

AMW Appoints Additional Experts for Drug Delivery Systems to its Scientific Advisory Board   Warngau, Germany, July 1, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Miriam Breunig, Senior Academic Councillor at the University of Regensburg's Department of Pharmaceutical Technology, and Prof. Karsten Mäder, Professor of Pharmaceutics at Martin Luther University Halle-Wittenberg, as members to AMW’s Scientific Advisory Board. Following the departure of long-standing members Dr. Dirk Schrader and Dr. Georg Ingram, the Board once again consists of three members with Prof. Olivia Merkel, who has been a member of the Scientific Advisory Board since the beginning of 2023. “We are delighted to welcome Prof. Breunig and Prof. Mäder to our Scientific Advisory Board,” said Philipp Karbach, CEO of AMW. “At the same time, we would like to express our sincere thanks to Dr. Schrader and Dr. Ingram for their many years of support for AMW. The development that our company has undergone in recent years has been made possible not least by their support and professional expertise. Our high-profiled Scientific Advisory Board will continue to support us in the future on scientific topics and strategic matters and will accompany AMW's growth path with a focus on biodegradable drug delivery systems.” “It is a tremendous advantage for AMW to benefit from Scientific Advisory Board members with such extensive R&D expertise,” added Dr. Eric Wittchow, Vice President R&D of AMW. “Our focus on research and development of innovative drug delivery systems will be further strengthened by the intensive exchange with our Scientific Advisory Board, and I am very much looking forward to our future collaboration.” Prof. Breunig’s work at University of Regensburg's Department of Pharmaceutical Technology focuses on developing innovative drug delivery systems for small molecules and biologics like proteins and nucleic acids, which significantly enhances patient-centric therapies. In addition, her work has been instrumental in understanding the interaction between nanoparticulate materials and biological tissues to improve the design of drug delivery systems. Prof. Mäder is specialized in biodegradable polymers and drug delivery systems. His research at Martin Luther University Halle-Wittenberg concentrates on nano-drug delivery systems, its noninvasive characterization, parenteral controlled release forms, and enhancing oral bioavailability. In very close cooperation with clinicians he develops new drug delivery systems for the treatment of dental diseases, the eye and the inner ear. Further information on the members of AMW’s Scientific Advisory Board can be found on our website at https://lnkd.in/ePUkxBya

🌟 Teams in Bewegung: AMW Running Event Recap! 🌟 We are thrilled to share the highlights from our recent participation in the Hasenöhrllauf (https://lnkd.in/eDURwSV8) in Geitau, where 25 dedicated AMW team members came together on June 5 to participate for the third time in this annual run! 🏃♂️🏃♀️ Under the motto "Teams in Bewegung," we focused on the power of togetherness over competition. It's all about building strong connections and enjoying the journey as a team. 💪 Here are some highlights: 👉 The Challenge: Conquering a beautiful 5.7 km course, surrounded by scenic views and great company. Very well captured in the pictures below, showing our team before and after the successful run. 👉 Exclusive Gear: Each participant proudly wore a high-quality AMW running shirt made from Merino wool, symbolizing our commitment to excellence and sustainability. 👉 Growth: We nearly doubled our participant count from last year, showcasing our growing spirit and enthusiasm. 👉 Teambuilding Fun: An evening filled with movement, delicious food, and an amazing atmosphere, capped off with an unforgettable After-Show-Party at the "Hasenöhrl-Stadl".   A huge thank you to everyone who participated and made this event a success. Let’s keep moving, supporting each other, and creating lasting memories! 🙌 #AMWTeam #Teambuilding #Hasenöhrllauf #CompanyCulture

Doors open at BIO 2024, meet with us in San Diego   Join AMW GmbH at BIO 2024, June 3-6 in San Diego, where we will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 4315-15 in the German Pavilion. See you there!   Team on site: Dr. Andrey Molchanov, Joerg Serafimov, PhD, João Silva, Kristian Laufer   #BIO2024    See the event site for further information: 👉 https://lnkd.in/dKrXuHVa BIO One-on-One Partnering system: 👉 https://lnkd.in/ecR9Dzg3

AMW GmbH Again Reports Record Financial Results 2023, CEO Philipp Karbach Becomes Shareholder, Investment Program For Employees Launched   Warngau, Germany, June 3, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2023. AMW posted a 2023 consolidated record revenue of EUR 29.4 million and achieved operating profitability for the second consecutive year. In addition, the Company reported a partial change in its shareholder structure combined with an offer for employees to become a shareholder in AMW on attractive terms (“AMW Evolution program”). AMW reported a 2023 consolidated record revenue of EUR 29.4 million, compared to EUR 22.8 million for the 2022 financial year (+29%), and achieved operating profitability for the second consecutive year. The rise in revenues was mainly driven by increased sales of AMW’s implants goserelin and leuprorelin as well as an upturn in revenues from manufacturing activities. Endomedica GmbH, AMW’s wholly owned subsidiary, and responsible for marketing leuprorelin as Leugon® in Germany, also contributed significantly to the Company’s overall revenues achieving the third consecutive sales record in a row. At the beginning of 2024, a partial change to AMW’s shareholder structure has been implemented. AMW Beteiligungsgesellschaft mbH & Co KG, which is predominantly owned by CEO Philipp Karbach, has taken over 23.66% of AMW’s shares. In addition, the “AMW Evolution program” has been set up to offer an opportunity for employees to participate in the Company’s long-term success by acquiring a specified number of shares at attractive conditions. “We are extremely proud to have successfully continued our growth trajectory also in the 2023 financial year,” commented Philipp Karbach, CEO of AMW. “Our strategic focus on biodegradable implants and our uncompromising commitment to customer orientation are paying off. To allow our employees to participate in AMW’s successful development, I have decided on the ‘AMW Evolution program’. This is a decisive step for us to focus the entire team even more on the successful implementation of our strategy and to give those the opportunity to become proud shareholders who give their best every day. I am very pleased with the positive response and the interest shown so far. It makes me proud to continue pursuing our strategy of providing high-quality medicines to patients worldwide together with my dedicated team as joint shareholders.” 👉 https://lnkd.in/ernAjmbZ

Join AMW GmbH at BIO 2024 in San Diego from June 3-6 and discover how our groundbreaking advancements are shaping the future of biotechnology. We will be on site with our Business Development and Licensing Teams and are looking forward to meeting you at our booth no. 4315-15 in the German Pavilion. Or secure your meeting slot via the BIO One-on-One Partnering system. Let's connect at this incredible event and unlock new opportunities together.   See the event site for further information: 👉 https://lnkd.in/dKrXuHVa BIO One-on-One Partnering system:  👉 https://lnkd.in/ecR9Dzg3 #BIO2024 #Wherebusinessandbreakthroughsconverge

May we introduce you to one of AMW GmbH’s busiest teams?   Since May 2022, our company has proudly hosted two bee colonies in the rear area of our premises. It all began with a delightful encounter with our local beekeeper, who, alongside his wife, shared captivating tales about these remarkable creatures. On that memorable day, AMW employees, accompanied by their children, joined us to sow flower seeds, transforming our green space into a haven for our new industrious friends, ensuring a bountiful harvest of honey.   As autumn approaches, our bees will embark on their seasonal journey, seeking refuge with our trusted beekeeper for the winter months. Now entering their third year with us, we are thrilled to welcome them back once again.   Our honey has been savored by employees, customers, suppliers, and guests alike. It's a sweet testament to our commitment to nature and biodiversity. In a world where bee populations are dwindling, we recognized the importance of taking action. By providing a sanctuary for our buzzing friends, we contribute to the preservation of these vital pollinators and the ecosystems they support.   Today is World Bee Day, so let's celebrate the invaluable role of bees in sustaining life on Earth and reaffirm our pledge to safeguard their future. Together, we can make a difference.   #WorldBeeDay #SaveTheBees #BeeFriendlyBusiness

AMW GmbH Receives Notified Body Opinion by TÜV SÜD for its Leuprorelin Implant in Pre-Filled Syringe AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has received the final report of the Notified Body Opinion (NBO) for its leuprorelin implant in pre-filled syringes. The NBO completes a diligent conformity review procedure by a notified body, in this case TÜV SÜD. Thus, after official assessment, the applicator of the leuprorelin implant complies with the relevant general safety and performance requirements (Annex I) of the new European legislation, EU Regulation 2017/745 (MDR). “It is a great achievement for AMW, and we are very proud of having received the NBO for leuprorelin by TÜV SÜD”, commented Elisabeth Wood, Senior Regulatory Affairs Manager of AMW. “This shows high quality and regulatory compliance of our integral drug-device combination product and paves the way for further approvals of leuprorelin, thereby opening new markets within the European Union and beyond. After TÜV SÜD had already issued the NBO for goserelin in July last year, this now marks the second positive conformity assessment for our products within a short time.” Since May 26, 2021, a NBO (or CE marking) is a mandatory part of the EU registration procedure for integral drug-device combinations, such as AMW's goserelin and leuprorelin implants in pre-filled syringes. This procedure requires accurate and detailed documentation verifying the safety and performance of the applicator from release to the end of shelf-life of the medicinal product. AMW develops and produces innovative, bio-degradable sustained-release drug delivery systems, such as the GnRH analogue implants goserelin and leuprorelin. For global commercialization, the products are licensed to international and regional partners. AMW is the exclusive manufacturer and provider of these implants and receives royalties on licenses from its partners. 👉 https://lnkd.in/eMGTdpm8